GT201100017A - Derivados de piridazina como inhibidores de smo - Google Patents
Derivados de piridazina como inhibidores de smoInfo
- Publication number
- GT201100017A GT201100017A GT201100017A GT201100017A GT201100017A GT 201100017 A GT201100017 A GT 201100017A GT 201100017 A GT201100017 A GT 201100017A GT 201100017 A GT201100017 A GT 201100017A GT 201100017 A GT201100017 A GT 201100017A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- piridazine
- derivatives
- novedous
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE, EN TÉRMINOS GENERALES, A COMPUESTOS NOVEDOSOS EN RELACIÓN CON EL DIAGNÓSTICO Y EL TRATAMIENTO DE PATOLOGÍAS RELACIONADAS CON LA TRAYECTORIA DE HEDGEHOG, INCLUYENDO, PERO NO LIMITÁNDOSE A, FORMACIÓN DE TUMOR CÁNCER, NEOPLASIA, Y TRASTORNOS HIPERPROLIFERATIVOS NO MALIGNOS. LA PRESENTE INVENCIÓN INCLUYE COMPUESTOS NOVEDOSOS, COMPOSICIONES NOVEDOSAS, MÉTODOS PARA SU USO, Y MÉTODOS PARA SU FABRICACIÓN, EN DONDE ESTOS COMPUESTOS SON EN GENERAL FARMACOLÓGICAMENTE ÚTILES COMO AGENTES EN TERAPIAS CUYO MECANISMO DE ACCIÓN INVOLUCRA MÉTODOS PARA INHIBIR LA TOMORIGÉNESIS, EL CRECIMIENTO TUMORAL Y LA SOBREVIVENCIA DE TUMORES, UTILIZANDO AGENTES QUE INHIBEN LA TRAYECTORIA DE SEÑALIZACIÓN DE HEDGEHOG Y SMO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8190008P | 2008-07-18 | 2008-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201100017A true GT201100017A (es) | 2013-08-29 |
Family
ID=41130287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201100017A GT201100017A (es) | 2008-07-18 | 2011-01-18 | Derivados de piridazina como inhibidores de smo |
Country Status (44)
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
EP2294061A2 (en) | 2008-04-29 | 2011-03-16 | Eli Lilly & Company | Disubstituted phthalazine hedgehog pathway antagonists |
US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
US8536176B2 (en) * | 2008-08-01 | 2013-09-17 | Nippon Chemiphar Co., Ltd. | GPR119 agonist |
BRPI0920533A2 (pt) * | 2008-10-01 | 2020-12-15 | Novartis Ag | Antagonismo de estabilizado para o tratamento de distúrbios relacionados à trilha de porco-espinho |
PL2364185T3 (pl) | 2008-11-03 | 2013-10-31 | Lilly Co Eli | Dipodstawione ftalazyny jako antagoniści szlaku hedgehog |
KR101335770B1 (ko) | 2008-11-17 | 2013-12-12 | 일라이 릴리 앤드 캄파니 | 사치환된 피리다진 헷지호그 경로 길항제 |
SI2358698T1 (sl) | 2008-11-17 | 2012-11-30 | Lilly Co Eli | Tetrasubstituiran piridazin kot antagonist signalne poti hedgehog |
AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
MX2012005695A (es) * | 2009-11-18 | 2012-06-13 | Novartis Ag | Metodos y composiciones para el tratamiento de tumores solidos y otras malignidades. |
CN102753545A (zh) * | 2009-12-15 | 2012-10-24 | 盐野义制药株式会社 | 具有血管内皮脂酶抑制活性的噁二唑衍生物 |
AR080908A1 (es) | 2010-04-16 | 2012-05-16 | Novartis Ag | Formulaciones de un piridazin -bipirazinilo |
KR101564806B1 (ko) | 2010-05-13 | 2015-10-30 | 암젠 인크 | Pde10 저해제로서 유용한 질소 헤테로시클릭 화합물 |
EP2511273B8 (en) | 2011-04-15 | 2019-06-26 | Hivih | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
MX349011B (es) | 2011-06-02 | 2017-07-05 | Novartis Ag | Biomarcadores para terapia de inhibidor de hedgehog. |
WO2014046624A1 (en) * | 2012-09-21 | 2014-03-27 | Agency For Science, Technology And Research | A method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway |
GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
EP2821104A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
EP3092236B1 (en) * | 2014-01-06 | 2020-08-26 | Rhizen Pharmaceuticals S.A. | Novel glutaminase inhibitors |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
KR20170129802A (ko) | 2015-03-10 | 2017-11-27 | 아두로 바이오테크, 인코포레이티드 | "인터페론 유전자의 자극인자"-의존적 신호전달을 활성화하는 조성물 및 방법 |
EP3302428A1 (en) | 2015-06-04 | 2018-04-11 | Pellepharm Inc. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
WO2017019897A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
HRP20220436T1 (hr) | 2015-11-03 | 2022-05-27 | Janssen Biotech, Inc. | Protutijela koja se specifično vežu na pd-1 i njihove uporabe |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
BR112018076441A2 (pt) * | 2016-06-23 | 2019-04-09 | St. Jude Children´S Research Hospital | moduladores de molécula pequena de pantotenato quinases |
US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
US10548908B2 (en) | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
CN110461833A (zh) * | 2017-04-05 | 2019-11-15 | 拜耳作物科学股份公司 | 2-氨基-5-氧基烷基嘧啶衍生物及其用于防治不希望的植物生长的用途 |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
CA3086671A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
EP3731859A4 (en) | 2017-12-27 | 2021-09-22 | St. Jude Children's Research Hospital, Inc. | METHODS OF TREATMENT FOR DISORDERS ASSOCIATED WITH CASTOR |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
CN111270196B (zh) * | 2019-03-07 | 2022-03-04 | 苏州微创关节医疗科技有限公司 | 制备锆铌合金表面氧化陶瓷层的方法及应用 |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
CN114042069B (zh) * | 2021-10-22 | 2024-07-19 | 陕西国际商贸学院 | 一种5-取代哒嗪-4-胺衍生物、制备方法和用途 |
WO2023101438A1 (ko) * | 2021-11-30 | 2023-06-08 | 주식회사 헤지호그 | Smo 인간 항체 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1293565A (en) | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
US3668207A (en) * | 1970-01-22 | 1972-06-06 | Ciba Geigy Corp | 2-amino-4-aryl-quinolines |
DE2643753A1 (de) | 1976-09-29 | 1978-04-06 | Thomae Gmbh Dr K | Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine |
FR2421900A1 (fr) | 1977-03-17 | 1979-11-02 | Sauba Lab | Piperazino-3-indoles, leur procede de preparation et leurs applications therapeutiques |
FI70411C (fi) * | 1980-12-29 | 1986-09-19 | Pfizer | Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat |
US5001125A (en) | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
US4569934A (en) * | 1984-10-09 | 1986-02-11 | American Cyanamid Company | Imidazo[1,2-b]pyridazines |
CA1307786C (en) * | 1984-12-14 | 1992-09-22 | Keiichi Yokoyama | Quinazoline derivatives and antihypertensive preparations containing same as effective components |
US4760064A (en) * | 1984-12-18 | 1988-07-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds, compositions containing same and processes for preparing same |
JP2544939B2 (ja) | 1987-09-01 | 1996-10-16 | 大塚製薬株式会社 | ベンゾヘテロ環誘導体 |
JPH0531271Y2 (es) | 1987-10-14 | 1993-08-11 | ||
JPH02193992A (ja) | 1989-01-23 | 1990-07-31 | Kyowa Hakko Kogyo Co Ltd | キナゾリン誘導体 |
JPH03106875A (ja) | 1989-09-20 | 1991-05-07 | Morishita Pharmaceut Co Ltd | 1―(3―ピリジルメチル)フタラジン誘導体 |
US5849741A (en) | 1994-08-09 | 1998-12-15 | Eisai Co., Ltd. | Fused pyridazine compounds |
US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5935958A (en) * | 1996-07-01 | 1999-08-10 | Schering Corporation | Muscarinic antagonists |
ATE427300T1 (de) | 1998-04-20 | 2009-04-15 | Abbott Gmbh & Co Kg | Heterocyclisch substituierte amide als calpainhemmer |
MY133108A (en) | 1998-06-30 | 2007-10-31 | Schering Corp | Muscarinic antagonists |
US6066636A (en) * | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
AU771234B2 (en) | 1999-01-28 | 2004-03-18 | Bristol-Myers Squibb Company | Antidepressant heterocyclic compounds |
JP2000281660A (ja) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | キナゾリン誘導体 |
BR0009507A (pt) | 1999-03-30 | 2002-01-15 | Novartis Ag | Derivados de ftalazina para o tratamento de doenças inflamatórias |
CZ20013940A3 (cs) | 1999-05-04 | 2002-04-17 | Schering Corporation | Piperazinové deriváty uľitečné jako CCR5 antagonisté |
ES2165274B1 (es) | 1999-06-04 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
JP2003501395A (ja) | 1999-06-08 | 2003-01-14 | ローランティス・リミテッド | 治療的使用 |
FR2803593B1 (fr) * | 2000-01-06 | 2002-02-15 | Sanofi Synthelabo | Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant |
AU2001252609A1 (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd. | Imidazopyridine derivatives |
DE10043659A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazinderivate |
ES2172436B1 (es) | 2000-10-31 | 2004-01-16 | Almirall Prodesfarma Sa | Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
EP1353674A1 (en) | 2000-12-29 | 2003-10-22 | Alteon, Inc. | Method for treating glaucoma ivb |
SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
JP2004534743A (ja) | 2001-04-09 | 2004-11-18 | ロランティス リミテッド | ヘッジホッグ |
JP4929547B2 (ja) | 2001-09-03 | 2012-05-09 | コニカミノルタホールディングス株式会社 | アゾメチン化合物、アゾメチン化合物と金属イオン含有化合物との混合物、感熱転写記録材料、カラートナー |
US7271261B2 (en) | 2001-10-19 | 2007-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted benzimidazoles and imidazo-[4,5]-pyridines |
DK1497266T3 (da) * | 2002-03-27 | 2008-10-06 | Glaxo Group Ltd | Quinolinderivater og deres anvendelse som 5HT6-ligander |
EP1997494A3 (en) | 2002-04-22 | 2009-06-10 | Johns Hopkins University School of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
EP1606282B1 (en) | 2003-02-24 | 2008-11-12 | Arena Pharmaceuticals, Inc. | Phenyl- and pyridylpipereidinye-derivatives as modulators of glucose metabolism |
SG145699A1 (en) | 2003-07-30 | 2008-09-29 | Xenon Pharmaceuticals Inc | Pyridazine derivatives and their use as therapeutic agents |
DE10337184A1 (de) | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
CA2535265C (en) | 2003-08-22 | 2014-01-28 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with trp-p8 expression |
US8067608B2 (en) | 2003-09-29 | 2011-11-29 | The Johns Hopkins University | Hedgehog pathway antagonists |
CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
KR20130083488A (ko) | 2004-09-02 | 2013-07-22 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
GB0422263D0 (en) * | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
DE102005023943A1 (de) | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln |
US20060281712A1 (en) * | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
US8364148B2 (en) * | 2005-07-07 | 2013-01-29 | Qualcomm Incorporated | Methods and devices for interworking of wireless wide area networks and wireless local area networks or wireless personal area networks |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
JP5225857B2 (ja) * | 2005-11-14 | 2013-07-03 | ジェネンテック,インコーポレイティド | ヘッジホッグシグナル伝達のビスアミド阻害剤 |
JP5144532B2 (ja) | 2005-11-30 | 2013-02-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | c−Met阻害剤及び用法 |
US8541406B2 (en) * | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
AR059898A1 (es) * | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
KR20080106970A (ko) | 2006-03-21 | 2008-12-09 | 쉐링 코포레이션 | Cxcr3 길항제 활성을 갖는 헤테로사이클릭 치환된 피리딘 화합물 |
CA2650704A1 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Salts of pyridazine compounds |
EP2063894B1 (en) | 2006-04-28 | 2019-08-28 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
EP1849781A1 (en) * | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
WO2007127475A2 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Pyridazines for demyelinating diseases and neuropathic pain |
AU2007272884A1 (en) | 2006-07-14 | 2008-01-17 | Pharmacopeia, Inc. | Heterocyclic substituted piperazine compounds with CXCR3 antagonist activity |
GB0623258D0 (en) * | 2006-11-22 | 2007-01-03 | Remynd Nv | Thiadiazole derivatives for the treatment of neuro-degenerative diseases |
AR064300A1 (es) | 2006-12-14 | 2009-03-25 | Syngenta Participations Ag | Pirandionas,tiopirandionas y ciclohexanotrionas como herbicidas |
JP2010513520A (ja) * | 2006-12-22 | 2010-04-30 | シェーリング コーポレイション | Cxcr3アンタゴニスト活性を有する複素環式化合物 |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
AR065622A1 (es) | 2007-03-07 | 2009-06-17 | Ortho Mcneil Janssen Pharm | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
MY156814A (en) | 2007-03-15 | 2016-03-31 | Novartis Ag | Organic compounds and their uses |
US8232274B2 (en) | 2007-03-15 | 2012-07-31 | Albany Molecular Research, Inc. | Pyridazinone derivatives useful as glucan synthase inhibitors |
WO2008110488A1 (en) | 2007-03-15 | 2008-09-18 | F. Hoffmann-La Roche Ag | Malonamides as orexin antagonists |
EP2188283B1 (en) * | 2007-09-07 | 2012-08-15 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
GB0808888D0 (en) * | 2008-05-15 | 2008-06-25 | Syngenta Participations Ag | Insecticidal compounds |
ES2398625T3 (es) | 2008-07-03 | 2013-03-20 | Janssen Pharmaceutica N.V. | 6-(1-Piperazinil)-piritazinas sustituidas como antagonistas de receptores 5-HT6 |
US20100029655A1 (en) * | 2008-07-11 | 2010-02-04 | Martin Robert Leivers | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them |
US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
US8216547B2 (en) | 2008-07-18 | 2012-07-10 | Janssen Pharmaceutica Nv | Radiolabelled TRP M8 receptor ligands |
AU2009272486A1 (en) | 2008-07-18 | 2010-01-21 | Takeda Pharmaceutical Company Limited. | Benzazepine derivatives and their use as hstamine H3 antagonists |
PE20110560A1 (es) | 2008-07-18 | 2011-08-29 | Sanofi Aventis | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET |
WO2010007317A1 (fr) | 2008-07-18 | 2010-01-21 | Sanofi-Aventis | NOUVEAUX DERIVES IMIDAZO[1,2-a]PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET |
FR2933982A1 (fr) | 2008-07-18 | 2010-01-22 | Sanofi Aventis | Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
ES2433469T3 (es) * | 2008-08-04 | 2013-12-11 | Amgen Inc. | Moduladores de la aurora cinasa y métodos de uso |
BRPI0920533A2 (pt) | 2008-10-01 | 2020-12-15 | Novartis Ag | Antagonismo de estabilizado para o tratamento de distúrbios relacionados à trilha de porco-espinho |
US7968128B2 (en) * | 2008-11-03 | 2011-06-28 | Viva Pharmaceutical Inc. | Plant extract compositions for affecting sleep |
PL2364185T3 (pl) * | 2008-11-03 | 2013-10-31 | Lilly Co Eli | Dipodstawione ftalazyny jako antagoniści szlaku hedgehog |
KR101335770B1 (ko) * | 2008-11-17 | 2013-12-12 | 일라이 릴리 앤드 캄파니 | 사치환된 피리다진 헷지호그 경로 길항제 |
FR2939134A1 (fr) * | 2008-12-01 | 2010-06-04 | Sanofi Aventis | Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
-
2009
- 2009-07-15 US US12/503,565 patent/US20100041663A1/en not_active Abandoned
- 2009-07-16 PE PE2011000050A patent/PE20110153A1/es not_active Application Discontinuation
- 2009-07-16 EA EA201100192A patent/EA020710B1/ru not_active IP Right Cessation
- 2009-07-16 AR ARP090102720A patent/AR072816A1/es unknown
- 2009-07-16 UA UAA201100571A patent/UA105181C2/uk unknown
- 2009-07-16 PT PT97806962T patent/PT2318389E/pt unknown
- 2009-07-16 WO PCT/EP2009/059138 patent/WO2010007120A1/en active Application Filing
- 2009-07-16 AU AU2009272719A patent/AU2009272719B2/en not_active Ceased
- 2009-07-16 JP JP2011517925A patent/JP5492202B2/ja not_active Expired - Fee Related
- 2009-07-16 MX MX2011000721A patent/MX2011000721A/es active IP Right Grant
- 2009-07-16 GE GEAP200912064A patent/GEP20125624B/en unknown
- 2009-07-16 NZ NZ590483A patent/NZ590483A/en not_active IP Right Cessation
- 2009-07-16 RS RS20130375A patent/RS52934B/en unknown
- 2009-07-16 BR BRPI0916375A patent/BRPI0916375A2/pt not_active IP Right Cessation
- 2009-07-16 PL PL09780696T patent/PL2318389T3/pl unknown
- 2009-07-16 UY UY0001031991A patent/UY31991A/es not_active Application Discontinuation
- 2009-07-16 CN CN2009801347026A patent/CN102143958B/zh not_active Expired - Fee Related
- 2009-07-16 MY MYPI2011000152A patent/MY149716A/en unknown
- 2009-07-16 DK DK09780696.2T patent/DK2318389T3/da active
- 2009-07-16 SI SI200930700T patent/SI2318389T1/sl unknown
- 2009-07-16 ME MEP-2011-6A patent/ME01290B/me unknown
- 2009-07-16 KR KR1020117003664A patent/KR101312122B1/ko active IP Right Grant
- 2009-07-16 CA CA2731130A patent/CA2731130C/en not_active Expired - Fee Related
- 2009-07-16 EP EP09780696.2A patent/EP2318389B1/en active Active
- 2009-07-16 JO JO2009269A patent/JO2843B1/en active
- 2009-07-16 ES ES09780696T patent/ES2428100T3/es active Active
- 2009-07-17 TW TW098124316A patent/TWI431001B/zh not_active IP Right Cessation
-
2011
- 2011-01-06 IL IL210494A patent/IL210494A/en not_active IP Right Cessation
- 2011-01-07 ZA ZA2011/00205A patent/ZA201100205B/en unknown
- 2011-01-10 CR CR20110014A patent/CR20110014A/es unknown
- 2011-01-14 MA MA33529A patent/MA32485B1/fr unknown
- 2011-01-17 CL CL2011000101A patent/CL2011000101A1/es unknown
- 2011-01-17 NI NI201100022A patent/NI201100022A/es unknown
- 2011-01-17 DO DO2011000020A patent/DOP2011000020A/es unknown
- 2011-01-17 CU CU2011000011A patent/CU24027B1/es active IP Right Grant
- 2011-01-18 SV SV2011003812A patent/SV2011003812A/es active IP Right Grant
- 2011-01-18 EC EC2011010764A patent/ECSP11010764A/es unknown
- 2011-01-18 GT GT201100017A patent/GT201100017A/es unknown
- 2011-01-18 HN HN2011000193A patent/HN2011000193A/es unknown
- 2011-01-19 CO CO11005445A patent/CO6351727A2/es active IP Right Grant
- 2011-09-21 HK HK11109939.2A patent/HK1155736A1/xx not_active IP Right Cessation
-
2012
- 2012-07-20 US US13/553,870 patent/US8481542B2/en active Active
-
2013
- 2013-05-30 US US13/905,686 patent/US9409871B2/en active Active
- 2013-09-10 HR HRP20130843AT patent/HRP20130843T1/hr unknown
- 2013-09-18 CY CY20131100808T patent/CY1114478T1/el unknown
- 2013-10-07 SM SMT201300114 patent/SMT201300114T1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201100017A (es) | Derivados de piridazina como inhibidores de smo | |
CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
CL2015001508A1 (es) | Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros. | |
GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
PA8740901A1 (es) | Compuestos organicos | |
PA8841901A1 (es) | Compuestos orgánicos | |
CL2011000134A1 (es) | Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer. | |
PA8819201A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
CR20110560A (es) | Métodos de tratamiento para tumores sólidos | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
ECSP11010867A (es) | Compuestos novedosos de fenilamino-isonicotinamida | |
CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
CR20120502A (es) | Uso de nuevos inhibidores de pan-cdk para tratar tumores | |
CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
ECSP088789A (es) | Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6 | |
TN2011000009A1 (en) | Pyridazne derivatives as smo inhibitors | |
DOP2009000143A (es) | Quinazolinas para la inhibicion de pdk1 | |
GT200800049A (es) | Derivados de 3-alquil-5 - (4-alquil-5-oxo- tetrahidrofuran-2-il) - pirrolidin-2-ona como intermediarios en la síntesis de inhibidores de renina | |
NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa | |
UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази |